查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1837194

动物治疗市场按产品类型、动物类型、给药途径、疾病类型、最终用户和分销管道划分－全球预测，2025-2032年

Veterinary Therapeutics Market by Product Type, Animal Type, Route Of Administration, Disease Type, End User, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，动物治疗市场规模将达到 724.2 亿美元，复合年增长率为 7.44%。

关键市场统计数据
基准年2024年 407.7亿美元
预计年份：2025年 437.5亿美元
预测年份 2032 724.2亿美元
复合年增长率 (%) 7.44%

一份简洁的指南，概述了动物疗法的范围、目标和策略意义，面向临床、商业和监管等各个领域的相关人员。

本执行摘要清晰阐述了动物治疗企业面临的策略和营运要务。透过设定涵盖产品创新、临床应用、监管动态、通路和终端用户工作流程的研究范围，后续分析得以置于切实可行的决策情境中。明确研究范围并提出关键问题，相关人员可以立即将自身内部优先事项与后续的证据和建议进行配对。

引言部分重点阐述了动物治疗领域为何值得经营团队关注，包括产品系列日益复杂、安全性和有效性预期不断提高、给药途径不断演变以及整合商业模式日益重要等问题。引言还概述了研究方法，重点介绍如何整合与临床医生和行业领袖的访谈、监管分析以及跨职能检验研讨会。最后，本部分提供了切实可行的见解，并论证了将研究结果纳入近期规划週期的策略价值。

重点分析变革性的技术、监管和经济变化如何再形成动物保健产业，并推动整个价值链的策略调整。

动物治疗领域正经历多重变革的交汇，这些变革正在重塑产品的研发、检验和动物应用方式。生技药品（包括细胞疗法、单株抗体和重组蛋白）的进步，拓展了传统小分子药物以外的治疗选择。同时，饲料添加剂（如酵素、益生元和益生菌）的创新，正将人们的关注点转向疾病预防和性能提升干预措施，而新一代杀寄生虫剂和精准疫苗则正在重新定义疾病管理策略。这些产品层面的转变正在改变研发週期、监管考量和商业化模式。

监理和商业动态同样重要。监管机构日益重视药物安全检测和真实世界证据，并要求申办单位建立更完善的上市后监测系统。同时，数位化分销管道和电子商务正在颠覆传统供应链，重塑与终端用户的关係。这些趋势，以及对抗生素管理和合理使用的日益重视，都要求企业采取跨职能协作的方式，将研发、监管事务、市场准入和商业运营有机结合起来。简而言之，为了实现长期价值，医药产业必须适应技术进步、日益严格的监管以及不断变化的客户期望。

对 2025 年美国累积关税如何改变动物治疗药物的供应链、成本结构和竞争动态进行基于证据的评估。

美国累积关税将于2025年生效，由此引发了一系列结构性压力，波及动物治疗产品的筹资策略、生产经济效益和分销计划。关税造成的成本差异迫使企业重新评估其全球供应商网络，并考虑近岸外包或区域生产，以确保利润率并确保供应的连续性。这种调整也影响产品生命週期管理，因为製造商必须权衡集中生产的效率和多元化区域生产能力的韧性之间的优点和缺点。

从商业性角度来看，关税政策提高了经销商、医院药局和零售商对成本透明度和合约弹性的重视程度。企业正在透过重新设计商业合约、签订多年供应协议以及加强库存管理来应对，以降低关税突发变化带来的风险。对于创新者和小型开发商而言，关税环境增加了市场决策的复杂性，并影响了合作伙伴的选择和定价策略。在这种环境下，那些积极重新设计供应链并加强与物流和分销合作伙伴协作的企业，将更有利于在应对利润压力的同时，保障动物群体的持续护理。

基于细分市场的洞察，将产品、动物、给药途径、疾病、最终用户和分销管道的细分转化为可操作的研发、商业化和服务交付策略。

深度细分洞察揭示了产品类型、动物群体、给药途径、疾病类型、终端用户和分销管道如何在治疗领域创造差异化的机会和挑战。按产品类型划分，生技药品（如细胞疗法、单株抗体和重组蛋白）需要特殊的低温运输物流和监管途径，这与饲料添加剂（如酵素、益生元和益生菌）显着不同。杀寄生虫药分为体外杀寄生虫药和体内杀寄生虫药，二者在抗药性管理上有差异。药品包括抗发炎药物、抗生素和激素，每种药物都有其独特的管理和处方动态。疫苗则因其不同的安全性特征和给药方案而有所区别，包括灭活疫苗、减毒活病毒疫苗疫苗和重组疫苗。

依产品类型进行细分会进一步影响产品设计和服务模式。水产养殖物种，例如甲壳类动物、淡水鱼和海水鱼，需要专门的给药系统和环境考量，这与伴侣动物（例如鸟类、犬、猫和囓齿动物）有所不同。家畜物种，例如牛、鸡、羊、山羊和猪，则优先考虑扩充性、经济高效且适用于畜群的干预措施。肠外给药方法，例如皮内、肌肉内、静脉和皮下给药，需要受过训练的人员和完善的给药通讯协定。特定疾病细分，例如行为障碍、感染疾病、代谢性疾病、肌肉骨骼疾病、寄生虫疾病和生殖障碍，会进一步影响临床试验设计和上市后支持需求，从而塑造证据生成策略。最终用户细分，例如门诊服务、线上管道、零售药局和兽医诊所，会影响购买行为、产品组合和教育需求。分销管道的选择，例如直销、电子商务、医​​院药房和零售药房，决定了物流、利润结构和客户覆盖范围。整合这些细分维度，可以帮助企业优先考虑投资，客製化资料产生策略，并设计符合各个细分市场细微需求的商业模式。

美洲、欧洲、中东和非洲以及亚太地区需求驱动因素、监管差异、物流限制和打入市场策略的区域整合

区域动态对法律规范、供应链设计和商业性执行有着深远的影响，并认识到这些差异对于制定协调一致的策略至关重要。在美洲，管理体制和兽医实践模式往往有利于先进疗法和完善的低温运输基础设施，而商业管道则由综合经销商和专业兽医医院网络组成。西半球内部的跨境贸易流动也影响采购决策和物流韧性。虽然西欧部分地区保持着严格的药物安全检测和渐进式的核准途径，但该区域内的其他司法管辖区在监管能力和市场进入复杂程度上存在差异，因此需要製定适应性强的市场进入和合规策略。

亚太地区呈现出独特的动态，包括某些市场对创新平台的快速采用、多样化的动物生产系统以及对畜牧业应用扩充性的重视。在地化生产能力、部分地区的监管现代化以及电子商务的显着渗透正在塑造新的市场管道。鑑于这些区域差异，企业必须制定差异化的策略，充分考虑监管差异、物流限制、价格敏感度和分销管道成熟度。对于寻求在这些地区实现可持续成长的企业而言，策略性的区域优先排序，辅以有针对性的伙伴关係和区域性临床证据计划，至关重要。

一份简明的企业格局评估报告，重点介绍领先动物保健公司的策略定位、创新轨迹、合作模式和竞争优势。

动物治疗产业格局复杂多样，既有成熟的製药公司，也有专业的生技药品开发商、契约製造，以及专注于细分市场或平台技术的敏捷型新兴企业。大型公司通常利用全球商业网络、强大的药物安全检测系统和整合的开发平臺来支持其广泛的产品系列，而专业公司则专注于高利润的治疗领域，例如单株抗体、细胞疗法和重组疫苗平台。受託製造厂商和物流专家发挥关键作用，他们能够实现规模化生产、低温运输管理，并建立灵活的生产布局，以适应关税主导的供应链变化。

伙伴关係、授权协议和策略性收购仍将是产能提升和市场渗透的关键机制。创新者与当地经销商和医院药房网路之间的合作能够加快产品上市速度，并减轻与当地监管机构沟通的负担。此外，投资于真实世界证据生成、数位化监管和临床医生教育的公司，将透过增强信任并证明产品的长期安全性和有效性，从而获得竞争优势。在这种环境下，差异化将不再主要取决于产品类别，而是更取决于公司如何整合治疗效果、供应可靠性以及为兽医和动物饲主提供的支援服务。

为帮助产业领导者适应监管变化、关税影响和不断变化的临床需求，同时加速永续成长和增强韧性，提供切实可行的策略建议。

行业领导者应采取一系列切实可行的策略，在保持商业性成长势头的同时，应对监管的复杂性、关税波动以及不断变化的临床需求。这些策略包括供应商多元化、评估关键零件的近岸外包以及加强库存管理以应对关税波动。其次，企业应加快对上市后监测和真实世界证据平台的投资，以满足日益增长的监管期望，并支持疫苗、生技药品和高触感药物的差异化提案主张。这样做将有助于加强风险管理，并为采购者和政策制定者提供令人信服的临床论点。

第三，策略性的商业性调整势在必行。企业应调整通路策略，根据需要充分利用线上通路和医院药局合作关係，同时与门诊服务机构和零售商保持紧密联繫，以确保产品广泛覆盖。第四，研发组合的优先排序应基于细分市场标准，并考虑给药途径、物种特异性需求和疾病负担等因素。最后，企业领导者必须在整个生态系统中建立合作伙伴关係，包括与契约製造、物流供应商和区域经销商的合作，以加速市场准入并管控营运风险。协调一致地落实这些建议，将有助于企业应对短期挑战，同时为长期价值创造奠定基础。

调查方法和资料来源的透明度：我们解释了支撑我们研究结论和相关人员信心的资料来源、分析框架、细分逻辑和品管。

本分析的调查方法结合了定性和定量方法，以确保研究结果的稳健性和可重复性，并为决策提供有力支持。主要研究包括对来自不同地区的临床医生、监管专家、供应链经理和商业领袖进行结构化访谈，以深入了解实际营运情况。次要研究整合了监管指导文件、临床文献和行业报告，以检验和阐释主要研究的趋势。透过与相关领域专家举办交叉检验研讨会，进行三角验证，以消除观点差异并探讨策略意义。

此分析架构采用基于产品类型、动物类别、给药途径、疾病类型、最终用户和分销管道的细分逻辑，以挖掘可操作的差异化因素。品管包括资讯来源检验、调查方法审核和情境测试，以评估对关键假设（例如关税调整和监管政策变化）的敏感性。在适用情况下，应用证据等级制度来优先考虑更高品质的临床和监管资讯来源。这种多层次的调查方法确保了结论得到多元化资讯来源的支持，并建议具有可操作性和说服力。

对各项结论进行简明扼要的综合分析，将策略意义、营运重点和投资考量连结起来，形成一个连贯的叙述，供决策者和相关人员参考。

总之，动物治疗领域正处于曲折点，其驱动力包括技术创新、不断变化的监管环境和转变的商业性模式。那些采用系统观点，将产品开发、供应链设计、监管策略和通路执行有机结合的研发机构，将更有能力将科学进步转化为持久的市场差异化优势。先进生技药品、不断发展的疫苗平台以及不断变化的给药偏好所带来的综合影响，要求我们整合证据并积极与相关人员进行有效沟通。

展望未来，韧性和适应性将决定竞争优势。那些积极应对关税和物流压力、主动重塑供应链、投资于上市后证据体系、并根据生产线和终端用户的细微需求定制产品的公司，将获得不成比例的巨大价值。最终的成功取决于严谨的优先顺序、策略伙伴关係关係，以及将研究成果转化为能够改善临床疗效并维持商业性绩效的营运方案的能力。这种整合应成为决策者制定短期和中期行动计画的策略指南。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 将人工智慧融入诊断影像技术，以增强兽医疾病的检测和治疗方案的发展。
  • 针对伴侣动物慢性发炎疾病的物种特异性单株抗体疗法的研发
  • 新型抗菌肽的出现可对抗家畜群体中的多重抗药性细菌感染疾病
  • 基因编辑技术（例如 CRISPR）在治疗马和牛的遗传疾病方面的进步
  • 提高小动物疼痛管理中长效注射剂的监管核准
  • 支持老年宠物关节健康和活动能力的营养补充剂和机能性食品市场成长
  • 利用物联网设备和高级分析技术，在酪农快速实施数据驱动的畜群健康计划

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：依产品类型分類的动物治疗市场

  • 生物製药
    • 细胞疗法
    • 单株抗体
    • 重组蛋白
  • 饲料添加剂
    • 酵素
    • 益生元
    • 益生菌
  • 杀寄生虫剂
    • 体外寄生虫杀灭剂
    • Endectocides
  • 製药
    • 抗发炎药
    • 抗生素
    • 荷尔蒙
  • 疫苗
    • 惰性
    • 减毒活病毒疫苗
    • 重组

第九章：以动物类型分類的动物治疗市场

  • 水产养殖
    • 甲壳类动物
    • 淡水鱼
    • 海水鱼
  • 伴侣动物
    • 鸟类
    • 狗
    • 猫
    • 囓齿动物
  • 马
    • 马术
    • 赛马
    • 休閒马匹
  • 家畜
    • 牛
    • 家禽
    • 绵羊和山羊
    • 猪

第十章：依给药途径分類的动物治疗药物市场

  • 吸入
  • 口服
  • 肠外
    • 皮内注射
    • 肌肉注射
    • 静脉
    • 皮下
  • 外用

第十一章：依疾病类型分類的动物治疗市场

  • 行为障碍
  • 感染疾病
  • 代谢紊乱
  • 肌肉骨骼疾病
  • 寄生虫病
  • 生殖障碍

第十二章：按最终用户分類的动物治疗市场

  • 门诊服务
  • 线上管道
  • 零售药房
  • 兽医诊所

第十三章：按通路分類的动物治疗市场

  • 直销
  • 电子商务
  • 医院药房
  • 零售药房

第十四章：按地区分類的动物治疗市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 按群体分類的动物治疗市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章：各国动物治疗药物市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Zoetis Inc.
    • Merck & Co., Inc.
    • Boehringer Ingelheim International GmbH
    • Elanco Animal Health Incorporated
    • Bayer Aktiengesellschaft
    • Ceva Sante Animale SA
    • Virbac SA
    • Vetoquinol SA
    • Dechra Pharmaceuticals PLC
    • Phibro Animal Health Corporation
Product Code: MRR-034B500303A2

The Veterinary Therapeutics Market is projected to grow by USD 72.42 billion at a CAGR of 7.44% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 40.77 billion
Estimated Year [2025] USD 43.75 billion
Forecast Year [2032] USD 72.42 billion
CAGR (%) 7.44%

A concise orientation that outlines the scope, objectives, and strategic relevance of veterinary therapeutics to stakeholders across clinical, commercial, and regulatory domains

This executive summary opens with a clear orientation that frames the strategic and operational imperatives facing organizations engaged in veterinary therapeutics. It establishes the scope of inquiry across product innovation, clinical application, regulatory dynamics, distribution pathways, and end-user workflows, thereby situating subsequent analysis within a pragmatic decision-making context. By defining the boundaries of the research and articulating the primary questions addressed, stakeholders can immediately align internal priorities with the evidence and recommendations that follow.

The introduction emphasizes why veterinary therapeutics warrants heightened executive attention: rising complexity in product portfolios, accelerating expectations for safety and efficacy, evolving routes of administration, and the growing importance of integrated commercial models. It also outlines the methodological approach at a high level, highlighting the synthesis of primary interviews with clinicians and industry leaders, secondary regulatory analysis, and cross-functional validation workshops. Ultimately, this opening section sets expectations for actionable insights and signals the strategic value of integrating research findings into near-term planning cycles.

A focused analysis of transformative technological, regulatory, and economic shifts reshaping veterinary therapeutics and driving strategic realignment across the value chain

The veterinary therapeutics landscape is undergoing several convergent transformations that are reconfiguring how products are developed, validated, and delivered to animal populations. Advances in biologics, including cell therapies, monoclonal antibodies, and recombinant proteins, are expanding therapeutic options beyond traditional small-molecule pharmaceuticals. Concurrently, innovation in feed additives such as enzymes, prebiotics, and probiotics is shifting attention toward preventive and performance-enhancing interventions, while next-generation parasiticides and precision vaccines are redefining disease control strategies. These product-level shifts are altering development timelines, regulatory considerations, and commercialization models.

Equally important are regulatory and commercial dynamics. Regulatory authorities are increasingly emphasizing pharmacovigilance and real-world evidence, prompting sponsors to build stronger post-market surveillance infrastructures. At the same time, digital distribution channels and e-commerce are disrupting conventional supply chains and reshaping interactions with end users. Together with greater emphasis on antimicrobial stewardship and responsible use, these trends require companies to adopt cross-functional approaches that bridge R&D, regulatory affairs, market access, and commercial operations. In short, the industry must adapt to technological progress, heightened oversight, and changing customer expectations to capture long-term value.

An evidence-based appraisal of how the cumulative United States tariffs enacted in 2025 are altering supply chains, cost structures, and competitive dynamics in veterinary therapeutics

The cumulative implementation of United States tariffs in 2025 introduced a set of structural pressures that ripple across sourcing strategies, manufacturing economics, and distribution planning for veterinary therapeutics. Tariff-induced cost differentials have compelled organizations to re-evaluate global supplier networks and to consider nearshoring or regional manufacturing to preserve margin and ensure supply continuity. This recalibration has implications for product lifecycle management, as manufacturers must weigh the trade-offs between centralized production efficiencies and the resilience offered by diversified regional capacity.

From a commercial standpoint, tariffs have elevated the importance of cost transparency and contract flexibility among distributors, hospital pharmacies, and retail partners. Companies are responding by redesigning commercial agreements, securing multi-year supplier commitments, and enhancing inventory management practices to mitigate exposure to sudden duty changes. For innovators and smaller developers, the tariff environment has increased the complexity of market entry decisions, influencing partner selection and pricing strategies. In this environment, organizations that proactively redesign their supply chains and strengthen collaborative relationships with logistics providers and distribution partners will be better positioned to maintain continuity of care for animal populations while managing margin pressure.

Segment-driven insights that translate product, animal, administration, disease, end-user, and distribution segmentations into practical implications for R&D, commercialization, and service delivery

Deep segmentation insight reveals how distinct product categories, animal populations, administration routes, disease types, end users, and distribution channels create differentiated opportunities and constraints across the therapeutic landscape. Product-wise, biologics such as cell therapies, monoclonal antibodies, and recombinant proteins demand specialized cold-chain logistics and regulatory pathways that differ markedly from feed additives like enzymes, prebiotics, and probiotics, which focus on preventive benefits and on-farm integration. Parasiticides split into ectoparasiticides and endectocides with divergent resistance management needs, while pharmaceuticals encompass anti-inflammatories, antibiotics, and hormones that each have unique stewardship and prescription dynamics. Vaccines present another axis of differentiation where inactivated, live attenuated, and recombinant platforms carry distinct safety profiles and administration protocols.

Animal-type segmentation further shapes product design and service models. Aquaculture modalities such as crustaceans, freshwater fish, and marine fish require specialized delivery systems and environmental considerations that differ from companion animals like avian, canine, feline, and rodents, which demand high-touch clinical interfaces and owner-focused communication. Equine populations-performance horses, racing horses, and recreational horses-present heterogenous therapeutic priorities tied to performance, regulatory testing, and owner investment, whereas livestock segments such as cattle, poultry, sheep and goats, and swine prioritize scalability, cost-efficiency, and herd-level interventions. Route of administration also maps to both product development and user preference: inhalation and oral options facilitate ease of use for certain species, while parenteral approaches, including intradermal, intramuscular, intravenous, and subcutaneous methods, require trained personnel and robust delivery protocols. Disease-type segmentation-behavioral disorders, infectious diseases, metabolic disorders, musculoskeletal disorders, parasitic diseases, and reproductive disorders-further informs clinical trial design and post-market support needs, shaping evidence generation strategies. End-user distinctions across ambulatory services, online channels, retail pharmacies, and veterinary hospitals influence purchasing behavior, product bundling, and educational requirements, and distribution channel choices between direct sales, e-commerce, hospital pharmacies, and retail pharmacies determine logistics, margin structures, and customer reach. By integrating these segmentation dimensions, companies can prioritize investments, tailor evidence generation, and design commercial models that align with the nuanced needs of each market niche.

A regional synthesis of demand drivers, regulatory divergence, logistical constraints, and market access strategies across the Americas, Europe, Middle East & Africa, and Asia-Pacific

Regional dynamics exert a powerful influence on regulatory frameworks, supply chain design, and commercial execution, and recognizing these distinctions is essential for coherent strategy. In the Americas, regulatory regimes and veterinary practice patterns tend to favor advanced therapeutics and robust cold-chain infrastructure, while commercial channels exhibit a blend of consolidated distributors and specialized veterinary hospital networks. Cross-border trade flows within the hemisphere also shape sourcing decisions and logistics resilience. Moving across to Europe, Middle East & Africa, regulatory heterogeneity becomes a defining characteristic: while parts of Western Europe maintain stringent pharmacovigilance and progressive approval pathways, other jurisdictions within the broader region present varying levels of regulatory capacity and market access complexity, requiring adaptable market entry and compliance strategies.

The Asia-Pacific region brings its own set of dynamics, including rapid adoption of innovative platforms in certain markets, diverse animal production systems, and a strong emphasis on scalability for livestock applications. Local manufacturing capabilities, regulatory modernization in some jurisdictions, and significant e-commerce penetration are shaping new routes to market. Given these regional contrasts, companies must design differentiated approaches that account for regulatory divergence, logistics constraints, pricing sensitivity, and distribution channel maturity. Strategic regional prioritization, supported by targeted partnerships and localized clinical evidence plans, will be instrumental for organizations seeking sustainable growth across these geographies.

A concise corporate landscape assessment highlighting strategic positioning, innovation trajectories, partnership patterns, and competitive differentiators across leading veterinary therapeutics firms

The corporate landscape in veterinary therapeutics reflects a mix of established pharmaceutical firms, specialized biologics developers, contract manufacturers, and agile startups that focus on niche segments or platform technologies. Larger firms typically leverage global commercial networks, robust pharmacovigilance systems, and integrated R&D pipelines to support broad product portfolios, whereas specialized companies concentrate on high-margin therapeutic niches such as monoclonal antibodies, cell therapies, or recombinant vaccine platforms. Contract manufacturing organizations and logistics specialists play a critical role by enabling scale-up, cold-chain management, and flexible production footprints that can respond to tariff-driven supply chain shifts.

Partnerships, licensing agreements, and strategic acquisitions continue to be primary mechanisms for capability development and market entry. Collaboration between innovators and regional distributors or hospital pharmacy networks accelerates access while reducing the burden of local regulatory navigation. Moreover, companies that invest in real-world evidence generation, digital surveillance, and clinician education secure competitive advantages by strengthening trust and demonstrating long-term safety and efficacy. In this environment, differentiation derives less from basic product classes and more from how firms orchestrate integrated solutions that combine therapeutic efficacy, supply reliability, and support services for veterinarians and animal owners.

Actionable strategic recommendations that equip industry leaders to adapt to regulatory changes, tariff impacts, and evolving clinical needs while accelerating sustainable growth and resilience

Industry leaders should adopt a set of pragmatic strategies to address regulatory complexity, tariff disruption, and evolving clinical needs while preserving commercial momentum. First, organizations must redesign supply chain architectures to prioritize resilience; this includes diversifying supplier bases, evaluating nearshoring for critical components, and strengthening inventory controls to buffer against tariff volatility. Second, companies should accelerate investments in post-market surveillance and real-world evidence platforms to meet heightened regulatory expectations and to support differentiated value propositions for vaccines, biologics, and high-touch pharmaceuticals. By doing so, they will enhance risk management and provide compelling clinical narratives to purchasers and policy makers.

Third, strategic commercial realignment is necessary: firms should recalibrate channel strategies to leverage online channels and hospital pharmacy partnerships where appropriate while maintaining strong relationships with ambulatory services and retail outlets for broad access. Fourth, R&D portfolios ought to be prioritized using segmentation-informed criteria that consider route of administration, species-specific needs, and disease burden; focusing resources on platforms with clear clinical and logistical advantages will improve return on development effort. Finally, leaders must cultivate collaborative partnerships across the ecosystem, including contract manufacturers, logistics providers, and regional distributors, to accelerate market entry and manage operational risk. Implementing these recommendations in a coordinated manner will help organizations navigate near-term headwinds while positioning for long-term value creation.

Methodological transparency describing data sources, analytical frameworks, segmentation logic, and quality controls that underpin the research conclusions and stakeholder confidence

The research methodology underpinning this analysis combines qualitative and quantitative approaches to ensure robust, reproducible findings and to support confident decision making. Primary research included structured interviews with clinicians, regulatory experts, supply chain managers, and commercial leaders across varied geographies to capture real-world operational insights. Secondary research integrated regulatory guidance documents, clinical literature, and industry reports to validate trends and contextualize primary findings. Triangulation occurred through cross-validation workshops with subject matter experts to reconcile divergent views and to refine implications for strategy.

Analytical frameworks employed segmentation logic across product types, animal categories, routes of administration, disease types, end users, and distribution channels to surface actionable differentiation. Quality controls included source verification, methodological audits, and scenario testing to assess sensitivity to key assumptions such as tariff shifts and regulatory policy changes. Wherever applicable, evidence hierarchies were applied to prioritize higher-quality clinical and regulatory sources. This layered methodological approach ensures that conclusions are grounded in diverse evidence streams and that recommendations are both pragmatic and defensible.

A succinct concluding synthesis that ties strategic implications, operational priorities, and investment considerations into a coherent narrative for decision makers and stakeholders

In conclusion, the veterinary therapeutics sector stands at an inflection point driven by technological innovation, regulatory evolution, and shifting commercial architectures. Organizations that adopt a systems perspective-aligning product development, supply chain design, regulatory strategy, and channel execution-will be better equipped to convert scientific advances into durable market differentiation. The combined effects of advanced biologics, evolving vaccine platforms, and changing administration preferences necessitate integrated evidence generation and robust stakeholder engagement.

Looking ahead, resilience and adaptability will define competitive advantage. Firms that proactively redesign supply networks in response to tariff and logistical pressures, invest in post-market evidence systems, and tailor offerings to the nuanced needs of species and end users will capture disproportionate value. Ultimately, success will depend on disciplined prioritization, strategic partnerships, and the ability to translate research into operational programs that improve clinical outcomes and sustain commercial performance. This synthesis should serve as a strategic compass for decision makers planning near- and medium-term actions.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of artificial intelligence in diagnostic imaging to enhance veterinary disease detection and treatment planning
  • 5.2. Development of species-specific monoclonal antibody therapies targeting chronic inflammatory conditions in companion animals
  • 5.3. Emergence of novel antimicrobial peptides to combat multidrug-resistant bacterial infections in livestock populations
  • 5.4. Advancement of gene editing technologies such as CRISPR for treatment of hereditary diseases in equine and bovine patients
  • 5.5. Increasing regulatory approval of long-acting injectable formulations for pain management in small animal practice
  • 5.6. Growth of nutraceutical and functional food products to support joint health and mobility in aging companion animals
  • 5.7. Rapid implementation of data-driven herd health programs leveraging IoT devices and advanced analytics in dairy farms

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Veterinary Therapeutics Market, by Product Type

  • 8.1. Biologics
    • 8.1.1. Cell Therapies
    • 8.1.2. Monoclonal Antibodies
    • 8.1.3. Recombinant Proteins
  • 8.2. Feed Additives
    • 8.2.1. Enzymes
    • 8.2.2. Prebiotics
    • 8.2.3. Probiotics
  • 8.3. Parasiticides
    • 8.3.1. Ectoparasiticides
    • 8.3.2. Endectocides
  • 8.4. Pharmaceuticals
    • 8.4.1. Anti-Inflammatories
    • 8.4.2. Antibiotics
    • 8.4.3. Hormones
  • 8.5. Vaccines
    • 8.5.1. Inactivated
    • 8.5.2. Live Attenuated
    • 8.5.3. Recombinant

9. Veterinary Therapeutics Market, by Animal Type

  • 9.1. Aquaculture
    • 9.1.1. Crustaceans
    • 9.1.2. Freshwater Fish
    • 9.1.3. Marine Fish
  • 9.2. Companion Animals
    • 9.2.1. Avian
    • 9.2.2. Canine
    • 9.2.3. Feline
    • 9.2.4. Rodents
  • 9.3. Equine
    • 9.3.1. Performance Horses
    • 9.3.2. Racing Horses
    • 9.3.3. Recreational Horses
  • 9.4. Livestock
    • 9.4.1. Cattle
    • 9.4.2. Poultry
    • 9.4.3. Sheep & Goats
    • 9.4.4. Swine

10. Veterinary Therapeutics Market, by Route Of Administration

  • 10.1. Inhalation
  • 10.2. Oral
  • 10.3. Parenteral
    • 10.3.1. Intradermal
    • 10.3.2. Intramuscular
    • 10.3.3. Intravenous
    • 10.3.4. Subcutaneous
  • 10.4. Topical

11. Veterinary Therapeutics Market, by Disease Type

  • 11.1. Behavioral Disorders
  • 11.2. Infectious Diseases
  • 11.3. Metabolic Disorders
  • 11.4. Musculoskeletal Disorders
  • 11.5. Parasitic Diseases
  • 11.6. Reproductive Disorders

12. Veterinary Therapeutics Market, by End User

  • 12.1. Ambulatory Services
  • 12.2. Online Channels
  • 12.3. Retail Pharmacies
  • 12.4. Veterinary Hospitals

13. Veterinary Therapeutics Market, by Distribution Channel

  • 13.1. Direct Sales
  • 13.2. E-Commerce
  • 13.3. Hospital Pharmacies
  • 13.4. Retail Pharmacies

14. Veterinary Therapeutics Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Veterinary Therapeutics Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Veterinary Therapeutics Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Zoetis Inc.
    • 17.3.2. Merck & Co., Inc.
    • 17.3.3. Boehringer Ingelheim International GmbH
    • 17.3.4. Elanco Animal Health Incorporated
    • 17.3.5. Bayer Aktiengesellschaft
    • 17.3.6. Ceva Sante Animale S.A.
    • 17.3.7. Virbac S.A.
    • 17.3.8. Vetoquinol S.A.
    • 17.3.9. Dechra Pharmaceuticals PLC
    • 17.3.10. Phibro Animal Health Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ANIMAL TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ANIMAL TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS VETERINARY THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA VETERINARY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA VETERINARY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA VETERINARY THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE VETERINARY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST VETERINARY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA VETERINARY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC VETERINARY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN VETERINARY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC VETERINARY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION VETERINARY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS VETERINARY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 VETERINARY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO VETERINARY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. VETERINARY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. VETERINARY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. VETERINARY THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY CELL THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY CELL THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY CELL THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY CELL THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY CELL THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY CELL THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY RECOMBINANT PROTEINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY RECOMBINANT PROTEINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY RECOMBINANT PROTEINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY RECOMBINANT PROTEINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY FEED ADDITIVES, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY FEED ADDITIVES, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY FEED ADDITIVES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY FEED ADDITIVES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY FEED ADDITIVES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY FEED ADDITIVES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY FEED ADDITIVES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY FEED ADDITIVES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ENZYMES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ENZYMES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ENZYMES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ENZYMES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ENZYMES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ENZYMES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PREBIOTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PREBIOTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PREBIOTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PREBIOTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PREBIOTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PREBIOTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PROBIOTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PROBIOTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PROBIOTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PROBIOTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PROBIOTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PROBIOTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PARASITICIDES, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PARASITICIDES, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PARASITICIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PARASITICIDES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PARASITICIDES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PARASITICIDES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PARASITICIDES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PARASITICIDES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ECTOPARASITICIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ECTOPARASITICIDES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ECTOPARASITICIDES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ECTOPARASITICIDES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ECTOPARASITICIDES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ECTOPARASITICIDES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ENDECTOCIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ENDECTOCIDES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ENDECTOCIDES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ENDECTOCIDES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ENDECTOCIDES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ENDECTOCIDES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PHARMACEUTICALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PHARMACEUTICALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PHARMACEUTICALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PHARMACEUTICALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PHARMACEUTICALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PHARMACEUTICALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY HORMONES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY HORMONES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY HORMONES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY HORMONES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY HORMONES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY HORMONES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY VACCINES, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY INACTIVATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY INACTIVATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY INACTIVATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY INACTIVATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY LIVE ATTENUATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY LIVE ATTENUATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY LIVE ATTENUATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY LIVE ATTENUATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY RECOMBINANT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY RECOMBINANT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY RECOMBINANT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY AQUACULTURE, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY AQUACULTURE, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY AQUACULTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY AQUACULTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY AQUACULTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY AQUACULTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY AQUACULTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY AQUACULTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY CRUSTACEANS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY CRUSTACEANS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY CRUSTACEANS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY CRUSTACEANS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY CRUSTACEANS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY CRUSTACEANS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY FRESHWATER FISH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY FRESHWATER FISH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY FRESHWATER FISH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY FRESHWATER FISH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY FRESHWATER FISH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY FRESHWATER FISH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY MARINE FISH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY MARINE FISH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY MARINE FISH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY MARINE FISH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY MARINE FISH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY MARINE FISH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY COMPANION ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY COMPANION ANIMALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY COMPANION ANIMALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY COMPANION ANIMALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY COMPANION ANIMALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY COMPANION ANIMALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY COMPANION ANIMALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY AVIAN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY AVIAN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY AVIAN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY AVIAN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY AVIAN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY AVIAN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY CANINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY CANINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY CANINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY CANINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY CANINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY CANINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY FELINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY FELINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY FELINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY FELINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY FELINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY FELINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY RODENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY RODENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY RODENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY RODENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY RODENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY RODENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY EQUINE, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY EQUINE, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY EQUINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY EQUINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY EQUINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY EQUINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY EQUINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY EQUINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PERFORMANCE HORSES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PERFORMANCE HORSES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PERFORMANCE HORSES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PERFORMANCE HORSES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PERFORMANCE HORSES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PERFORMANCE HORSES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY RACING HORSES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY RACING HORSES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY RACING HORSES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY RACING HORSES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY RACING HORSES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY RACING HORSES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY RECREATIONAL HORSES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY RECREATIONAL HORSES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY RECREATIONAL HORSES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY RECREATIONAL HORSES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY RECREATIONAL HORSES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY RECREATIONAL HORSES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY LIVESTOCK, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY LIVESTOCK, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY LIVESTOCK, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY LIVESTOCK, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY LIVESTOCK, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY LIVESTOCK, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY LIVESTOCK, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY LIVESTOCK, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY CATTLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY CATTLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY CATTLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY CATTLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY CATTLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY CATTLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY POULTRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY POULTRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY POULTRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY POULTRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY POULTRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY POULTRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY SHEEP & GOATS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY SHEEP & GOATS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY SHEEP & GOATS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY SHEEP & GOATS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY SHEEP & GOATS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY SHEEP & GOATS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY SWINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY SWINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY SWINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY SWINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY SWINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY SWINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY INHALATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY INHALATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY INHALATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY INHALATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY INHALATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY INTRADERMAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY INTRADERMAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY INTRADERMAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY INTRADERMAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY INTRADERMAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY INTRADERMAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 295. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 296. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 297. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 298. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY TOPICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 299. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 300. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 301. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 302. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 303. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY BEHAVIORAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 304. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY BEHAVIORAL DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 305. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY BEHAVIORAL DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 306. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY BEHAVIORAL DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 307. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY BEHAVIORAL DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 308. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY BEHAVIORAL DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 309. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 310. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 311. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 312. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 313. GLOBAL VETERINARY THERAPEUTICS MARKET SIZE, BY